ADULT T-CELL LEUKEMIA/LYMPHOMA
Clinical trials for ADULT T-CELL LEUKEMIA/LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ADULT T-CELL LEUKEMIA/LYMPHOMA trials appear
Sign up with your email to follow new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising new cocktail targets tough leukemia in early trial
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, azacitidine, chidamide, vindesine, and dexamethasone) in adults newly diagnosed with a rare, aggressive leukemia called ETP-ALL. The goal is to see if this mix can help more patients achieve remission. About 27 people will…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New Two-Step transplant aims to cut deaths in blood cancer patients
Disease control Recruiting nowThis study tests a two-step approach to bone marrow transplant using lower doses of radiation and chemotherapy before the transplant. The goal is to see if this gentler method reduces the number of patients who die from treatment side effects. The study includes adults with vario…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New hope: drug may stop lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC